118 related articles for article (PubMed ID: 32572918)
1. Linc00601 upregulation promotes hepatocellular carcinoma development by activating MAPK signaling pathway.
Wang YC; Hu BH; Zhang WW; Li MM; Zhao X; Sui MH
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6039-6045. PubMed ID: 32572918
[TBL] [Abstract][Full Text] [Related]
2. C-MYC-induced upregulation of LINC01503 promotes progression of non-small cell lung cancer.
Zhang ML; Zhao TT; Du WW; Yang ZF; Peng W; Cui ZJ
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(21):11120-11127. PubMed ID: 33215429
[TBL] [Abstract][Full Text] [Related]
3. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway.
Zhang Q; Cheng S; Cao L; Yang J; Wang Y; Chen Y
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32077915
[TBL] [Abstract][Full Text] [Related]
4. STAT1-induced upregulation of lncRNA LINP1 promotes cell proliferation and inhibits apoptosis via AMPK signaling pathway in papillary thyroid cancer.
Li HP; Yang TZ; Wei L; Ge YF; Meng QS
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8911-8917. PubMed ID: 32964981
[TBL] [Abstract][Full Text] [Related]
5. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
Li SJ; Sui MH; Sun ZX; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
7. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma.
Ding K; Liao Y; Gong D; Zhao X; Ji W
Biochem Biophys Res Commun; 2018 Jul; 502(2):194-201. PubMed ID: 29800569
[TBL] [Abstract][Full Text] [Related]
8. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
9. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
10. SP1-regulated LINC01638 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.
Guo L; Fang L; Liu Y
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8913-8920. PubMed ID: 31696478
[TBL] [Abstract][Full Text] [Related]
11. LncRNA RUNX1-IT1 inhibits proliferation and promotes apoptosis of hepatocellular carcinoma by regulating MAPK pathways.
Yan PH; Wang L; Chen H; Yu FQ; Guo L; Liu Y; Zhang WJ; Bai YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8287-8294. PubMed ID: 31646558
[TBL] [Abstract][Full Text] [Related]
12. LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway.
Wu JH; Tian XY; An QM; Guan XY; Hao CY
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1645-1652. PubMed ID: 29630107
[TBL] [Abstract][Full Text] [Related]
13. LINC01198 promotes colorectal cancer cell proliferation and inhibits apoptosis via Notch signaling pathway.
Chen S; Yuan H; Chen BC; Wan ZA; Tu SL; Hu XY
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8439-8446. PubMed ID: 32894550
[TBL] [Abstract][Full Text] [Related]
14. Silencing of linc00337 inhibits proliferation, cell cycle progression, migration, and invasion of colorectal cancer cells through the MEK/ERK pathway.
Wang ZG; Yang YG; Fu GS; Lu DH; Tian SY; Wei W
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5353-5359. PubMed ID: 32495869
[TBL] [Abstract][Full Text] [Related]
15. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
16. LINC01535 promotes proliferation and inhibits apoptosis in esophageal squamous cell cancer by activating the JAK/STAT3 pathway.
Fang Y; Zhang S; Yin J; Shen YX; Wang H; Chen XS; Tang H
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3694-3700. PubMed ID: 32329845
[TBL] [Abstract][Full Text] [Related]
17. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
18. Promoting effect of PAX5-activated lncRNA UASR1 on growth of colorectal cancer by regulating the mTOR pathway.
Wang W; Wang Z; Wang H; Li X; Wang HT
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2986-2993. PubMed ID: 32271416
[TBL] [Abstract][Full Text] [Related]
19. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
Ma CX; Gao WC; Tian L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
[TBL] [Abstract][Full Text] [Related]
20. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Wu JZ; Jiang N; Lin JM; Liu X
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
